{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:14:12Z","timestamp":1788484452246,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Radioactively labeled somatostatin analogs (SSAs) are used in PET imaging of meningiomas due to the high expression of somatostatin receptor (SSTR) subtype 2.\n                      <jats:sup>18<\/jats:sup>\n                      F-labeled SSTR-tracers offer several economic and logistical advantages over\n                      <jats:sup>68<\/jats:sup>\n                      Ga-labeled tracers, such as a cyclotron-based production, higher activities per synthesis, a lower positron energy resulting in improved spatial resolution, and a longer half-life. Owing to the advantages over the most commonly used\n                      <jats:sup>68<\/jats:sup>\n                      Ga-labeled SSAs, [\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE - although not yet approved by FDA or EMA - is currently in clinical use. The study compares [\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE PET uptake with histological SSTR2-expression in meningiomas.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A correlation of SUV values and immunohistochemical SSTR2-expression was performed in 12 patients (42% female, mean age 68.8\u2009\u00b1\u20097.2 years). This study demonstrates a strong and significant correlation between [\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE uptake (SUV\n                      <jats:sub>mean<\/jats:sub>\n                      ) and histological SSTR2-immune-reactivity-score (SSTR2-IRS) values (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.80;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). In addition, a significant difference in [\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE uptake (SUV\n                      <jats:sub>mean<\/jats:sub>\n                      ) was observed between low SSTR-expressing lesions (scores 0\u20131) and high SSTR-expressing lesions (scores 2\u20133;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006). Furthermore, it was noted that in four cases, the molecular tumor volume (MTV) was underestimated using a threshold value of SUV\n                      <jats:sub>min<\/jats:sub>\n                      4, presumably caused by a low SUV\n                      <jats:sub>max<\/jats:sub>\n                      , while the application of a 50% isocontour threshold led to an underestimation of the MTV in two lesions that showed high SUV\n                      <jats:sub>max<\/jats:sub>\n                      values.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]SiTATE PET shows a strong and significant correlation with SSTR2-expression in meningiomas. However, neither of the two threshold methods yielded MTVs comparable to MRI volumes in all cases. Further studies are necessary to identify the conditions under which each threshold value yields the best MTV.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-026-01505-w","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:35:21Z","timestamp":1788482121000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Correlation of [18F]SiTATE-PET-tracer with somatostatin receptor expression in meningiomas: an exploratory ex vivo histological pilot study"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9128-6670","authenticated-orcid":false,"given":"Rieke","family":"Gerdes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Schittenhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Reischl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0306-1143","authenticated-orcid":false,"given":"Hannes","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Tatagiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador G.","family":"Castaneda-Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7519-0417","authenticated-orcid":false,"given":"Christian","family":"la Foug\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3397-6299","authenticated-orcid":false,"given":"Nils F.","family":"Trautwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"issue":"11","key":"1505_CR1","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","volume":"23","author":"R Goldbrunner","year":"2021","unstructured":"Goldbrunner R, Stavrinou P, Jenkinson MD, Sahm F, Mawrin C, Weber DC, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021;23(11):1821\u201334.","journal-title":"Neuro Oncol"},{"key":"1505_CR2","doi-asserted-by":"crossref","unstructured":"Ogasawara C, Philbrick BD, Adamson DC, Meningioma. A Review of Epidemiology, Pathology, Diagnosis, Treatment, and Future Directions. Biomedicines. 2021;9(3):316 .","DOI":"10.3390\/biomedicines9030319"},{"issue":"Suppl 5","key":"1505_CR3","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","volume":"24","author":"QT Ostrom","year":"2022","unstructured":"Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015\u20132019. Neuro Oncol. 2022;24(Suppl 5):v1\u201395.","journal-title":"Neuro Oncol"},{"issue":"1","key":"1505_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4132\/jptm.2019.11.05","volume":"54","author":"YS Lee","year":"2020","unstructured":"Lee YS, Lee YS. Molecular characteristics of meningiomas. J Pathol Transl Med. 2020;54(1):45\u201363.","journal-title":"J Pathol Transl Med"},{"issue":"20","key":"1505_CR5","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1038\/onc.2010.609","volume":"30","author":"M Kalamarides","year":"2011","unstructured":"Kalamarides M, Stemmer-Rachamimov AO, Niwa-Kawakita M, Chareyre F, Taranchon E, Han ZY, et al. Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. Oncogene. 2011;30(20):2333\u201344.","journal-title":"Oncogene"},{"issue":"8","key":"1505_CR6","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231\u201351.","journal-title":"Neuro Oncol"},{"key":"1505_CR7","doi-asserted-by":"publisher","first-page":"123988","DOI":"10.1016\/j.wneu.2025.123988","volume":"198","author":"R Zuniga","year":"2025","unstructured":"Zuniga R, Carrijo GS, do Vale MR, Reis B, da Veiga GRL, de Aguiar PHP, et al. Pathogenic Variants and Prognosis in Meningiomas: A Systematic Review and Meta-Analysis. World Neurosurg. 2025;198:123988.","journal-title":"World Neurosurg"},{"issue":"Suppl 1","key":"1505_CR8","first-page":"i84","volume":"5","author":"N Galldiks","year":"2023","unstructured":"Galldiks N, Albert NL, Wollring M, Werner JM, Lohmann P, Villanueva-Meyer JE, et al. Advances in PET imaging for meningioma patients. Neurooncol Adv. 2023;5(Suppl 1):i84\u201393.","journal-title":"Neurooncol Adv"},{"issue":"10","key":"1505_CR9","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.2967\/jnumed.125.270115","volume":"66","author":"R Ebner","year":"2025","unstructured":"Ebner R, Braach J, Rubenthaler J, Cyran CC, Sheikh GT, Brendel M, et al. Retrospective Evaluation of the Correlation Between Somatostatin Receptor PET\/CT and Histopathology in Patients with Suspected Intracranial Meningiomas. J Nucl Med. 2025;66(10):1561\u20137.","journal-title":"J Nucl Med"},{"issue":"12","key":"1505_CR10","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1007\/s00259-024-06783-x","volume":"51","author":"NL Albert","year":"2024","unstructured":"Albert NL, Preusser M, Traub-Weidinger T, Tolboom N, Law I, Palmer JD, et al. Joint EANM\/EANO\/RANO\/SNMMI practice guideline\/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0. Eur J Nucl Med Mol Imaging. 2024;51(12):3662\u201379.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"1505_CR11","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1007\/s00259-023-06315-z","volume":"50","author":"M Unterrainer","year":"2023","unstructured":"Unterrainer M, Kunte SC, Unterrainer LM, Holzgreve A, Delker A, Lindner S, et al. Next-generation PET\/CT imaging in meningioma-first clinical experiences using the novel SSTR-targeting peptide [(18)F]SiTATE. Eur J Nucl Med Mol Imaging. 2023;50(11):3390\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1505_CR12","doi-asserted-by":"publisher","first-page":"835","DOI":"10.2967\/jnumed.123.265622","volume":"64","author":"H Leupe","year":"2023","unstructured":"Leupe H, Ahenkorah S, Dekervel J, Unterrainer M, Van Cutsem E, Verslype C, et al. (18)F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use. J Nucl Med. 2023;64(6):835\u201341.","journal-title":"J Nucl Med"},{"issue":"1","key":"1505_CR13","first-page":"59","volume":"6","author":"IH Olsen","year":"2016","unstructured":"Olsen IH, Langer SW, Federspiel BH, Oxb\u00f8l J, Loft A, Berthelsen AK, et al. 68Ga-DOTATOC PET and gene expression profile in patients with neuroendocrine carcinomas: strong correlation between PET tracer uptake and gene expression of somatostatin receptor subtype 2. Am J Nucl Med Mol Imaging. 2016;6(1):59\u201372.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"1505_CR14","doi-asserted-by":"crossref","unstructured":"Hennrich U, Benesova M. [(68)Ga]Ga-DOTA-TOC: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging. Pharmaceuticals (Basel). 2020;13(3):38.","DOI":"10.3390\/ph13030038"},{"key":"1505_CR15","unstructured":"Administration USFaD. Approval Letter for Ga 68 DOTATOC Injection. 2019.[Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/210828Orig1s000Approv.pdf Accessed 2026-01-05]]."},{"key":"1505_CR16","unstructured":"Administration USFaD. Original Approval Letter for NETSPOT (Gallium Ga-68 dotatate). 2016.[Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2016\/208547Orig1s000ltr.pdf Accessed 2026-01-05]]."},{"key":"1505_CR17","unstructured":"Agency EM, EPAR Public Assessment Report. : SomaKit TOC (68Ga-DOTA-Tyr\u00b3-octreotide) \u2013 Radiopharmaceutical kit for PET imaging. 2016.[Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/somakit-toc-epar-public-assessment-report_en.pdf Accessed 2026-01-05]]."},{"key":"1505_CR18","doi-asserted-by":"crossref","unstructured":"Mansour N, Joram J, Grawe F, Hinterberger A, Rubenthaler J, Klambauer K, et al. Validation of SUV thresholds in [(1)(8)F]SiTATE PET\/CT for accurate meningioma segmentation. Eur J Nucl Med Mol Imaging. 2026;53(2):854\u201364.","DOI":"10.1007\/s00259-025-07476-9"},{"issue":"8","key":"1505_CR19","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/RLU.0000000000003607","volume":"46","author":"M Unterrainer","year":"2021","unstructured":"Unterrainer M, Lindner S, Beyer L, Gildehaus FJ, Todica A, Mittlmeier LM, et al. PET Imaging of Meningioma Using the Novel SSTR-Targeting Peptide 18F-SiTATE. Clin Nucl Med. 2021;46(8):667\u20138.","journal-title":"Clin Nucl Med"},{"issue":"8","key":"1505_CR20","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.2967\/jnumed.125.269619","volume":"66","author":"NF Trautwein","year":"2025","unstructured":"Trautwein NF, Mattern S, Hinterleitner M, Reischl G, Schirrmacher R, Steger V, et al. Histologic Ex Vivo Validation of the [(18)F]SITATE Somatostatin Receptor PET Tracer. J Nucl Med. 2025;66(8):1204\u20139.","journal-title":"J Nucl Med"},{"key":"1505_CR21","doi-asserted-by":"crossref","unstructured":"Calder\u00f3n E, Kiefer LS, Schmidt FP, Lan W, Brendlin AS, Reinert CP, et al. One-day dual-tracer examination in neuroendocrine neoplasms: a real advantage of low activity LAFOV PET imaging. Eur J Nucl Med Mol Imaging. 2025;52(7):2463\u201376.","DOI":"10.1007\/s00259-025-07073-w"},{"issue":"1","key":"1505_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40658-025-00720-z","volume":"12","author":"NF Trautwein","year":"2025","unstructured":"Trautwein NF, Calderon E, Linder PM, Reischl G, Driessen P, Lan W, et al. Low-activity [(18)F]-somatostatin receptor (SSTR) imaging using [(18)F]SiTATE on a long axial field-of-view PET\/CT scanner. EJNMMI Phys. 2025;12(1):13.","journal-title":"EJNMMI Phys"},{"issue":"1","key":"1505_CR23","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1007\/s12672-025-04079-6","volume":"16","author":"SC Kunte","year":"2025","unstructured":"Kunte SC, Unterrainer LM, Lindner S, Holzgreve A, Kunz WG, Winkelmann M, et al. Feasibility of different meningioma delineation approaches on [(18)F]SiTATE PET\/CT imaging. Discov Oncol. 2025;16(1):2189.","journal-title":"Discov Oncol"},{"issue":"11","key":"1505_CR24","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/modpathol.3800954","volume":"20","author":"M Volante","year":"2007","unstructured":"Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol. 2007;20(11):1172\u201382.","journal-title":"Mod Pathol"},{"issue":"3","key":"1505_CR25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2967\/jnumed.114.149120","volume":"56","author":"W Rachinger","year":"2015","unstructured":"Rachinger W, Stoecklein VM, Terpolilli NA, Haug AR, Ertl L, Poschl J, et al. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J Nucl Med. 2015;56(3):347\u201353.","journal-title":"J Nucl Med"},{"issue":"1","key":"1505_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11060-025-05307-3","volume":"176","author":"L Ren","year":"2025","unstructured":"Ren L, Deng J, Xu J, Chan L, Xie Q, Wakimoto H, et al. SUV-max of (68)Ga-DOTATATE PET\/CT correlates with WHO grade and RNA risk classification in meningioma. J Neurooncol. 2025;176(1):37.","journal-title":"J Neurooncol"},{"issue":"3","key":"1505_CR27","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s11060-023-04414-3","volume":"164","author":"S Iglseder","year":"2023","unstructured":"Iglseder S, Iglseder A, Beliveau V, Heugenhauser J, Gizewski ER, Kerschbaumer J, et al. Somatostatin receptor subtype expression and radiomics from DWI-MRI represent SUV of [68Ga]Ga-DOTATOC PET in patients with meningioma. J Neurooncol. 2023;164(3):711\u201320.","journal-title":"J Neurooncol"},{"issue":"7","key":"1505_CR28","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1093\/neuonc\/now001","volume":"18","author":"M Sommerauer","year":"2016","unstructured":"Sommerauer M, Burkhardt JK, Frontzek K, Rushing E, Buck A, Krayenbuehl N, et al. 68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate? Neuro Oncol. 2016;18(7):1021\u20137.","journal-title":"Neuro Oncol"},{"issue":"9","key":"1505_CR29","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00259-012-2155-3","volume":"39","author":"A Afshar-Oromieh","year":"2012","unstructured":"Afshar-Oromieh A, Giesel FL, Linhart HG, Haberkorn U, Haufe S, Combs SE, et al. Detection of cranial meningiomas: comparison of (6)(8)Ga-DOTATOC PET\/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging. 2012;39(9):1409\u201315.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1505_CR30","doi-asserted-by":"publisher","first-page":"9064","DOI":"10.1038\/s41598-021-87866-9","volume":"11","author":"HC Einhellig","year":"2021","unstructured":"Einhellig HC, Siebert E, Bauknecht HC, Tietze A, Graef J, Furth C, et al. Comparison of diagnostic value of 68 Ga-DOTATOC PET\/MRI and standalone MRI for the detection of intracranial meningiomas. Sci Rep. 2021;11(1):9064.","journal-title":"Sci Rep"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-026-01505-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01505-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01505-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:56:24Z","timestamp":1788483384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-026-01505-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1505"],"URL":"https:\/\/doi.org\/10.1186\/s13550-026-01505-w","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was performed in accordance with the principles of the Declaration of Helsinki. This retrospective study was approved by the Institutional Review Board of the University Hospital of Tuebingen (089\/2024BO2). Written informed consent was obtained from all patients in accordance with the provisions of the German Pharmaceuticals Act \u00a713.2b. Each individual gave written informed consent to participate prior to imaging.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the participants for publication of this study and accompanying images.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N.T. received personal fees from Novartis outside the submitted work and was supported by the Clinician Scientist Program Tuebingen (525-0-0). An ongoing research collaboration exists between N.T. and C.l.F. with ABX. C.l.F. discloses research grant from Siemens Healthineers, Telix, and reports consulting fees from Siemens Healthineers, Novartis, Telix, Astra Zeneca and Bayer.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"134"}}